18 results
Brief Overview of Treatment Agents for COVID-19 - Version 2.01 4/11/2020

#Drugs #Medications #Treatment #COVID19 #Pharmacology #Table
Brief Overview of Treatment ... Agents for COVID ... 2020 #Drugs #Medications ... #Treatment #COVID19 ... #Pharmacology #Table
Drugs Used for the Treatment of COVID-19 Infection
LOPINAVIR / RITONAVIR
INTERFERON Beta-I
REMDESIVIR
HYDROXYCHLOROQUINE
TOCILIZUMAB

Piotr Okupski @PiotrOkupski - Original Infographic
Drugs Used for the Treatment ... of COVID-19 Infection ... smfarmhosp_smfh #Drugs #Medications ... #Treatment #COVID19 ... #Pharmacology #Table
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
DAAs #Antivirals #table ... #treatment #hcv ... #medications #infectiousdisease
Guillain-Barre Syndrome - Summary

Acute AIDP that presents with rapidly progressive flaccid weakness

Epidemiology:
 • 1-2 cases/100,000 per
Epidemiology: • 1- ... Pathophysiology ... like illnesses, COVID ... main variants: (1) ... Treatment: • Plasmapheresis
Drugs Used for the Treatment of COVID-19 Infection

** Editor Note (from ophthalmology MD input) - Hydroxychloroquine/chloroquine
Drugs Used for the Treatment ... of COVID-19 Infection ... smfarmhosp_smfh #Drugs #Medications ... #Treatment #COVID19 ... #Pharmacology #Table
Summary of Pharmacology for Select Proposed COVID-19 Treatments

#Pharmacology #Dosing #Table #COVID19 #Coronavirus #SARSCOV2 #Medications #JAMA
Select Proposed COVID ... -19 Treatments ... Pharmacology #Dosing #Table ... #COVID19 #Coronavirus ... #SARSCOV2 #Medications
Guillain-Barré Syndrome (GBS)
Acute autoimmune demyelinating polyradiculoneuropathy that presents with rapidly progressive flaccid weakness
Epidemiology:
 • Incidence: 1
Guillain-Barré Syndrome ... • Incidence: 1 ... 3 to 1/2 of patients ... the underlying pathophysiology ... and cauda equina TREATMENT
Rhabdomyolysis - Differential Diagnosis and Management Summary

Trauma:
 • Immobilization, Crush iniury, Compartment syndrome, Electrical injury
Exertional:
 •
Dermatomyositis) AKI - Pathophysiology ... : 1. ... oxidative iniury Treatment ... per day until stable ... Summary #causes #treatment
Long-Acting Injectable (LAI) - Atypical Antipsychotics 
INVEGA TRINZA 3 MONTHS 
ARISTADA 2 MONTHS 
INVEGA 1 MONTH
SUSTENNA
MONTHS INVEGA 1 ... MONTH ABILIFY 1 ... are used in the treatment ... Adherence to daily medications ... Pharmacists are able
Persistence of clinically relevant viruses on dry inanimate surfaces

Most common viruses persist on surfaces for days
Influenza virus 1 ... Parvovirus > 1 ... viruses #surfaces #infectiousdiseases ... #diagnosis #table ... contagiousness #COVID19